HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Tadashi Isomura Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hayashida, N. Articles by Aoyagi, S. Search for Related Content PubMed PubMed Citation Articles by Hayashida, N. Articles by Aoyagi, S.

J Thorac Cardiovasc Surg 1997;114:261-269
© 1997 Mosby, Inc.

CARDIOPULMONARY BYPASS, MYOCARDIAL MANAGEMENT, AND SUPPORT TECHNIQUES

EFFECTS OF MINIMAL-DOSE APROTININ ON CORONARY ARTERY BYPASS GRAFTING

Presented at the Sixty-ninth Scientific Sessions of the American Heart Association, New Orleans, La., Nov. 13, 1996.

Received for publication Oct. 21, 1996 Revisions requested Nov. 26, 1996; revisions received Jan. 11, 1997 Accepted for publication Feb. 21, 1997. Address for reprints: Nobuhiko Hayashida, MD, The Second Department of Surgery, Kurume University Hospital, 67 Asahi-machi, Kurume, Fukuoka, 830 Japan.

Abstract

Objective: To evaluate the effects of minimal-dose aprotinin in patients undergoing coronary artery bypass grafting, we conducted a prospective randomized study. Methods: A total of 167 patients were randomized to receive no aprotinin treatment (control, n = 57), minimal-dose aprotinin (1.0 x 10⁶ KIU; n = 55), or low-dose aprotinin (2.7 ± 0.5 x 10⁶ KIU; n = 55). Blood loss and transfusion requirements, parameters of clotting and fibrinolysis, renal function, and early graft patency rates were assessed. Results: Postoperative blood loss and transfusion requirements were significantly (p = 0.01) lower in both the minimal-dose and low-dose groups than in the control group. The increase in D-dimer level after cardiopulmonary bypass was significantly (p < 0.05) less marked in the low-dose group than in the control group. The ₂-plasmin inhibitor and plasminogen activator inhibitor–1 levels were significantly (p < 0.05) greater in the minimal-dose and low-dose groups than in the control group after bypass, suggesting the prevention of fibrinolysis by both aprotinin doses. No statistically significant differences in postoperative renal function and early vein graft patency rates were noted (control group, 93.8%; minimal-dose group, 98.5%; low-dose group, 92.3%; p = 0.25). Conclusions: Aprotinin was not associated with a significant increase in the prevalence of renal dysfunction or early vein graft occlusion. Minimal-dose aprotinin inhibited enhanced fibrinolytic activity and reduced blood loss and transfusion requirements after bypass equivalently to low-dose aprotinin. The dose of 1 x 10⁶ KIU added to the pump prime may be acceptably effective in reducing blood loss in patients undergoing primary coronary operations. J Thorac Cardiovasc Surg 1997;114:261-9

This article has been cited by other articles:

				X. Wang, Z. Zheng, H. Ao, S. Zhang, Y. Wang, H. Zhang, L. Li, and S. Hu A comparison before and after aprotinin was suspended in cardiac surgery: Different results in the real world from a single cardiac center in China J. Thorac. Cardiovasc. Surg., October 1, 2009; 138(4): 897 - 903. [Abstract] [Full Text] [PDF]

				J. R. Brown, N. J.O. Birkmeyer, and G. T. O'Connor Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery Circulation, June 5, 2007; 115(22): 2801 - 2813. [Abstract] [Full Text] [PDF]

				The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86. [Abstract] [Full Text] [PDF]

				S. W Sutton, M. A Duncan, V. A Chase, R. J Marcel, T. P Meyers, and R. E Wood Cardiopulmonary bypass and mitral valve replacement during pregnancy Perfusion, December 1, 2005; 20(6): 359 - 368. [Abstract] [PDF]

				D. Fergusson, K. C. Glass, B. Hutton, and S. Shapiro Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clinical Trials, June 1, 2005; 2(3): 218 - 232. [Abstract] [PDF]

				A. M. Mahdy and N. R. Webster Perioperative systemic haemostatic agents Br. J. Anaesth., December 1, 2004; 93(6): 842 - 858. [Abstract] [Full Text] [PDF]

				A. Sedrakyan, T. Treasure, and J. A. Elefteriades Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 442 - 448. [Abstract] [Full Text] [PDF]

				Y. Kaminishi, Y. Hiramatsu, Y. Watanabe, Y. Yoshimura, and Y. Sakakibara Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass Ann. Thorac. Surg., February 1, 2004; 77(2): 644 - 650. [Abstract] [Full Text] [PDF]

				J. M. Karski and J. T. Balatbat Blood Conservation Strategies in Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2003; 7(2): 175 - 188. [Abstract] [PDF]

				L. Englberger, B. Kipfer, P. A. Berdat, U. E. Nydegger, and T. P. Carrel Aprotinin in coronary operation with cardiopulmonary bypass: does "low-dose" aprotinin inhibit the inflammatory response? Ann. Thorac. Surg., June 1, 2002; 73(6): 1897 - 1904. [Abstract] [Full Text] [PDF]

				R. C. Landis, G. Asimakopoulos, M. Poullis, D. O. Haskard, and K. M. Taylor The antithrombotic and antiinflammatory mechanisms of action of aprotinin Ann. Thorac. Surg., December 1, 2001; 72(6): 2169 - 2175. [Abstract] [Full Text] [PDF]

				R. C. Landis, D. O. Haskard, and K. M. Taylor New antiinflammatory and platelet-preserving effects of aprotinin Ann. Thorac. Surg., November 1, 2001; 72(5): S1808 - 1813. [Abstract] [Full Text] [PDF]

				R. J. Dignan, D. W. Law, P. W. Seah, C. W. Manganas, D. C. Newman, P. W. Grant, and H. D. Wolfenden Ultra-low dose aprotinin decreases transfusion requirements and is cost effective in coronary operations Ann. Thorac. Surg., January 1, 2001; 71(1): 158 - 164. [Abstract] [Full Text] [PDF]

				F. Forestier, S. Belisle, D. Robitaille, R. Martineau, L. P. Perrault, and J.-F. Hardy Low-dose aprotinin is ineffective to treat excessive bleeding after cardiopulmonary bypass Ann. Thorac. Surg., February 1, 2000; 69(2): 452 - 456. [Abstract] [Full Text] [PDF]

				N. Hayashida, H. Tomoeda, T. Oda, E. Tayama, S. Chihara, T. Kawara, and S. Aoyagi Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass Ann. Thorac. Surg., November 1, 1999; 68(5): 1661 - 1667. [Abstract] [Full Text] [PDF]

				V. Mooser, F. Tinguely, P. Fontana, V. Lenain, M. Vaglio, P. Ruchat, L. K. von Segesser, S. M. Marcovina, M. Markert, R. Darioli, et al. Effect of Cardiopulmonary Bypass and Heparin on Plasma Levels of Lp(a) and Apo(a) Fragments Arterioscler Thromb Vasc Biol, April 1, 1999; 19(4): 1060 - 1065. [Abstract] [Full Text] [PDF]

				A. Alonso, C. W. Whitten, and G. E. Hill Pump prime only aprotinin inhibits cardiopulmonary bypass-induced neutrophil CD11b up-regulation Ann. Thorac. Surg., February 1, 1999; 67(2): 392 - 395. [Abstract] [Full Text] [PDF]

				F. Bizzarri, E. Carone, G. Capannini, G. Davoli, G. Lisi, M. Maccherini, G. Sani, and M. Toscano Bleeding reduction in cardiac surgery: A combined approach J. Thorac. Cardiovasc. Surg., May 1, 1998; 115(5): 1227 - 1227. [Full Text] [PDF]